MARC Record from Marygrove College

LEADER: 05403cam a22008294a 4500
001 ocn747167830
003 OCoLC
005 20191109071724.5
008 110815s2011 nyu b 000 0 eng
010 $a 2011034552
040 $aDNLM/DLC$beng$cDLC$dYDX$dBTCTA$dYDXCP$dNLM$dLIV$dZHB$dSRC$dIK2$dVP@$dUPZ$dBDX$dCDX$dOCLCO$dTTU$dOCLCO$dOCLCQ$dOCLCF$dOCLCQ$dDILBD$dFEM$dOCLCO$dOCLCA$dSFR$dOCLCQ$dOCLCO$dQQ3$dOCLCA$dJDP
016 7 $a101566935$2DNLM
019 $a706017786
020 $a9780525952404$q(hardback)
020 $a0525952403$q(hardback)
029 1 $aAU@$b000047608039
029 1 $aNLM$b101566935
029 1 $aNZ1$b13951013
035 $a(OCoLC)747167830$z(OCoLC)706017786
042 $apcc
043 $an-us---
050 00 $aHD9666.5$b.S54 2011
060 00 $a2011 K-184
060 10 $aQV 736
082 00 $a338.4/76153$223
049 $aMAIN
100 1 $aSharp, Kathleen.
245 10 $aBlood feud :$bthe man who blew the whistle on one of the deadliest prescription drugs ever /$cKathleen Sharp.
260 $aNew York :$bDutton/Penguin Group,$c©2011.
300 $aviii, 424 pages ;$c24 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
504 $aIncludes bibliographical references.
505 0 $aMeet and greet -- The deal -- Medicine road -- Raise the stakes -- The cancer indication -- Chosen one -- The deposition -- On the border -- Blues -- Quality of life -- Gaslighting -- The overdose plan -- The millionaires' club -- "Strength for living" -- Code mistress -- The arbitrator -- For the king -- Black ops -- The eleventh hour -- Twice saved -- Miracle gro -- Brothers -- The powers that spin -- The burden.
520 $a"Blood Feud is the electrifying true tale of Big Pharma's power, regulatory weakness, and the terrifying vulnerability of millions of innocent patients. THE PLAYERS The Drug: Procrit An anti-anemia drug, this miraculous blood booster was one of the first biotech blockbusters. Developed by Amgen and licensed to a Johnson & Johnson company, the drug was sold by the two companies under the brand names Procrit, Epogen, and Arenesp. The Underdog: Mark Duxbury, Drug Salesman Duxbury was the gung-ho salesman for the new biotech division of J & J, an irrepressible character full of jokes. In the early 1990s, he set out to spread the benefits of Procrit, and became a true believer and top seller. But he and his peers were told to steal business from J & J's partner, Amgen. Then came the marketing studies, the off-invoice rebates, doctor payments, and off-label claims. Duxbury tried to stop some of these ruthless programs, but was fired on trumped-up charges. He tried anything to warn the public: testifying in a secret arbitration, joining a class action effort, and filing a whistleblower suit. But he was thwarted at nearly every turn-until the surprising end. The Best Friend: Dean McClellan, Drug Legend Dean McClellan was Duxbury's friendly rival. He tried to beat his buddy's record and wound up selling $170 million worth of the drug, becoming a legend. When Duxbury got fired, McClellan tried to distance himself. But as news of Procrit's deadly power started to surface, McClellan agreed to hand over thousands of damning documents and help his friend blow the whistle on J & J. The Crusader: Jan Schlichtmann, Esq. Remember Jan Schlichtmann, protagonist of the best-selling book and Oscar nominated movie, A Civil Action? When he learned of Duxbury's mission, he felt the old fire rising in his belly and signed on. Now, he's gambling on yet another long shot, trying to fight on behalf of not just millions of cancer patients, but for every American who overpays for health-care"--Provided by publisher.
590 $bInternet Archive - 2
590 $bInternet Archive 2
600 10 $aDuxbury, Mark.
610 20 $aJohnson & Johnson.
600 12 $aDuxbury, Mark.
600 12 $aMcClellan, Dean.
600 12 $aSchlichtmann, Jan.
610 22 $aAmgen Inc.
610 22 $aJohnson & Johnson.
600 17 $aDuxbury, Mark.$2fast$0(OCoLC)fst01924943
610 27 $aJohnson & Johnson.$2fast$0(OCoLC)fst00693591
600 17 $aDuxbury, Mark.$2sears
610 27 $aJohnson & Johnson.$2sears
650 0 $aPharmaceutical industry$xCorrupt practices$zUnited States.
650 0 $aWhistle blowing$zUnited States$vCase studies.
650 12 $aDrug Industry$xeconomics.
650 12 $aErythropoietin$xeconomics.
650 22 $aAnemia$xdrug therapy.
650 22 $aErythropoietin$xadverse effects.
650 22 $aMarketing of Health Services$xeconomics.
650 22 $aWhistleblowing.
651 2 $aUnited States.
650 7 $aPharmaceutical industry$xCorrupt practices.$2fast$0(OCoLC)fst01060133
650 7 $aWhistle blowing.$2fast$0(OCoLC)fst01174586
651 7 $aUnited States.$2fast$0(OCoLC)fst01204155
650 7 $aPharmaceutical industry$xCorrupt practices.$2sears
650 7 $aWhistle blowing$zUnited States$vCase studies.$2sears
655 7 $aCase studies.$2fast$0(OCoLC)fst01423765
655 4 $aNonfiction.
655 7 $aCase studies.$2lcgft
938 $aBrodart$bBROD$n12755974$c$27.95
938 $aBaker and Taylor$bBTCP$nBK0009659748
938 $aCoutts Information Services$bCOUT$n17420165
938 $aYBP Library Services$bYANK$n6910517
994 $a92$bERR
976 $a31927002075346